Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tyrosine-protein phosphatase non-receptor type substrate 1 (SHPS-1), commonly known as Signal-regulatory protein alpha (SIRP-alpha) or CD172a, is a transmembrane glycoprotein predominantly expressed on myeloid cells, including macrophages, dendritic cells, and neutrophils, as well as in the central nervous system. It features three extracellular immunoglobulin-like domains and a cytoplasmic tail containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Upon binding to its ligand CD47, which is widely expressed on healthy cells and overexpressed on cancer cells as a 'don't eat me' signal, SIRP-alpha undergoes tyrosine phosphorylation. This recruits and activates the Src homology 2 (SH2) domain-containing protein tyrosine phosphatases SHP-1 and SHP-2, initiating an inhibitory signaling cascade that suppresses macrophage-mediated phagocytosis.
In oncology, the CD47-SIRP-alpha axis serves as a critical innate immune checkpoint that cancer cells exploit to evade immune surveillance. Therapeutic strategies targeting SIRP-alpha, such as monoclonal antibodies (e.g., BI 765063, ADU-1805, and BMS-986351), aim to block the CD47-SIRP-alpha interaction. This blockade restores the phagocytic capacity of macrophages, particularly when combined with tumor-opsonizing antibodies (such as rituximab or cetuximab) that provide a pro-phagocytic 'eat me' signal. Because SIRP-alpha expression is largely restricted to myeloid cells and neurons, targeting SIRP-alpha offers a wider therapeutic window and avoids the severe hematological toxicities (such as anemia and thrombocytopenia) associated with direct CD47-targeting agents.
Monoclonal antibodies targeting SIRP-alpha bind to its extracellular domain on myeloid cells, blocking its interaction with CD47 on tumor cells. This disrupts the inhibitory 'don't eat me' signal, promoting macrophage-mediated antibody-dependent cellular phagocytosis (ADCP) of cancer cells.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tyrosine-protein phosphatase non-receptor type substrate 1 (SIRPA).